Pulmonary vascular diseases
Hot topics
Disease modification in pulmonary arterial hypertension
Clinical
Aims : to describe the goal for new disease-modifying treatment of pulmonary arterial hypertension (PAH); to review whether the currently available treatments really change PAH evolution; to describe new therapies affecting different signalling pathways that may modify disease progression.
Target audience :
Adult pulmonologist/Clinician, Clinical researcher, General practitioner, Medical Student, Nurse, Patient, Physician in Pulmonary Training, Physiologist, Scientist (basic, translational)
Methods :
Cell and molecular biology, Physiology
10:15
Defining disease modification in PAH
S. Sahay(Houston, United States)
COI
-
Description
1
805
10:30
Are approved PAH drugs disease-modifying?
O. Sitbon(Le Kremlin-Bicêtre, France)
COI
-
Description
2
806
10:45
Sotatercept for the treatment of PAH: an update
M. Hoeper(Hannover, Germany)
COI
-
Description
3
807
11:00
Moving the field forward: novel pathways and targets for reverse remodelling
S. Savai Pullamsetti(Giessen, Germany)
COI
-
Description
4
808
11:15
Discussion and Q&A
5
809
. . .
